XNAS
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. Company operates in two reportable segments namely, Sales of Goods and Services. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2025-12-11 | Q3 2025 | -1.99 | -0.32 | +83.92% | $346,058 | ✅ Beat | — | — | — |
| 2025-09-09 | Q2 2025 | -0.17 | -0.18 | -5.88% | $622,452 | ❌ Miss | — | — | — |
| 2025-04-28 |
| Q4 2024 |
| — |
| -0.51 |
| — |
| $642,379 |
| — |
| -2.74% |
| +9.76% |
| +8.05% |
| 2024-12-04 | Q3 2024 | — | -0.12 | — | $645,796 | — | -6.44% | -8.28% | +16.55% |
| 2024-09-03 | Q2 2024 | — | -0.15 | — | $442,830 | — | -9.55% | -17.83% | +24.20% |
| 2024-05-31 | Q1 2024 | — | -0.21 | — | $408,532 | — | +13.03% | -4.59% | +9.91% |
| 2024-05-01 | Q4 2023 | — | -0.23 | — | $524,613 | — | +4.29% | -3.71% | +55.71% |
| 2023-12-13 | Q3 2023 | — | -0.22 | — | $427,841 | — | +0.00% | -6.37% | +8.61% |
Showing last 8 quarters.